Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma

Haematologica

Volumn 87, Issue 4, 2002, Pages 408-414

  Tosi, Patrizia ^a   Zamagni, Elena ^a   Cellini, Claudia ^a   Ronconi, Sonia ^a   Patriarca, Francesca ^a   Ballerini, Filippo ^a   Musto, Pellegrino ^a   Di Raimondo, Francesco ^a   Ledda, Antonio ^a   Lauria, Francesco ^a   Masini, Luciano ^a   Gobbi, Marco ^a   Vacca, Angelo ^a   Ria, Roberto ^a   Cangini, Delia ^a   Tura, Sante ^a   Baccarani, Michele ^a   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Multiple myeloma; Salvage therapy; Thalidomide

Indexed keywords

BETA 2 MICROGLOBULIN; M PROTEIN; THALIDOMIDE; VASCULOTROPIN;

ARTICLE; AUTOTRANSPLANTATION; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CAUSE OF DEATH; CELL CULTURE; CELL INFILTRATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG RESISTANCE; DRUG TOLERABILITY; FEMALE; HUMAN; LETHARGY; LEUKOPENIA; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PROTEIN DETERMINATION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

ADULT; AGED; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SALVAGE THERAPY; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036212935     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Plasma cell dyscrasias
2. Multiple myeloma
3. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials
4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
5. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
6. Allogeneic bone marrow transplantation in multiple myeloma
7. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma
8. Bone marrow neovascularization, plasma cell angiogenetic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
9. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis
10. Thalidomide is an inhibitor of angiogenesis
11. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
12. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs
13. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
14. + subset
15. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
16. Inhibition of IL-12 production by thalidomide
17. Antitumor activity of thalidomide in refractory multiple myeloma
18. Thalidomide alone or with dexamethasone for multiple myeloma
19. Therapy with thalidomide in refractory multiple myeloma patients: The revival of an old drug
20. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
21. Thalidomide in patients with advanced myeloma: Survival and prognostic factors
22. Proposed guidelines for protocol studies. II. Plasma Cell. Prepared by a Committee of the Chronic Leukemia-Myeloma Task Force, National Cancer Institute Myeloma
23. Nonparametric estimation from incomplete observations
24. Thalidomide in multiple myeloma: Lack of response of soft-tissue plasmacytomas
25. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients
26. The treatment of multiple myeloma
27. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant
28. Low-dose thalidomide sems to be effective in multiple myeloma
29. Efficacy of low-dose thalidomide (T) in multiple myeloma
30. Thalidomide for previously untreated indolent or smoldering multiple myeloma
31. Microvascular density and cytotoxic T cell activation correlates with response to thalidomide in multiple myeloma patients
32. Effect of thalidomide on myeloma cell apoptosis and VEGF secretion
33. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma
34. Thalidomide effects on apoptosis in multiple myeloma: Ex-vivo and in vitro studies
35. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma